Fine-tuned manipulation of the c-MET oncogenic pathway in pancreatic cancer: a new paradigm of personalised medicine.

只有8%的胰腺癌（PC）患者存活下来，目前的治疗方法在所有患者中都得到了有限的成功。超过三分之一的PC患者可能受益于一种针对癌细胞生长和存活的新型药物联合治疗。我们工作的意义在于确定可以针对PC患者的亚组选择性治疗策略，最终导致与这种致命癌症相关的死亡率降低。

Only 8% of patients with pancreatic cancer (PC) survive the disease, and current therapies, tested in all-comers, have limited success. More than a third of patients with PC may benefit from a novel combination therapy of agents that target cancer cell growth and survival. Significance of our work lies in identifying treatment strategies that can be directed to PC patients in a subgroup-selective manner, ultimately leading to reductions in the mortality associated with this lethal cancer.